Latest Breaking News On - Raising gross proceeds - Page 1 : comparemela.com

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesLas vegasObesity health forumTherapeutics incPrnewswire viking therapeutics incDrug administrationLigand pharmaceuticals incorporatedExchange commissionBofa securities health care conferenceTherapeutics reports first quarterProvides corporateFrom phasePlacebo adjusted weight lossFrom baselinePromising safety

Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Therapeutics incLigand pharmaceuticals incorporatedExchange commissionPositive top line resultsMedian liver fat reductionBiopsy results expectedObesity plannedResults expectedQuarter end cash positionViking therapeuticsQuarter endedRecent corporateObese patients plannedPositive phaseDemonstrating significant weight lossPromising safety

Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today Three Additional Data Announcements Expected in 2023Completed Enrollment in Phase 2b VOYAGE Study of VK2809 for NASH and Fibrosis; Data Expected in. | April 26, 2023

Therapeutics incLigand pharmaceuticals incorporatedPrnewswire viking therapeutics incExchange commissionAdditional data announcements expectedData expectedPlacebo adjusted mean weight lossPromising safetyEvaluating highly differentiated oral formulationResults expectedPublic offeringCommon stock raising gross proceedsQuarter ended marchBrian lianAnnounce dataEvaluating oral formulation

Crinetics Pharmaceuticals Reports First Quarter 2022

Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated.

United statesJames hassardChris robillardVivaldi coelhoMarc wilsonScott struthersCaren deardorfSecurities exchangeCrinetics pharmaceuticals incSanwa kagaku kenkyusho co ltdCrinetics pharmaceuticalsAscending dose dataCongenital hyperinsulinism patients plannedPrevious announcementPositive top line dataAscending dose